CLOMIPRAMINE HYDROCHLORIDE for Obsessive-Compulsive Disorder
About CLOMIPRAMINE HYDROCHLORIDEWhat research says
No current published assessment exists for this exact Treatment and Need. This does not establish benefit or no benefit.
Published assessment
Not reviewed
No published assessment to inspect
The exact pair exists, but a research conclusion has not been published. Absence of a review is not evidence of benefit or no benefit.
Find care
Choose a place to see published offerings. A listing does not confirm current availability.
Why this Treatment appears for this Need
Why this Treatment appears in the Need landscape, separate from the research conclusion.
See relationship sourceDailyMed clomipramine (Anafranil) label · checked Oct 16, 2026
Relationship: labeled indication
This statement’s scope
- Population
patients with Obsessive-Compulsive Disorder whose obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning (DSM-III-R); labeled effectiveness data include adults and children and adolescents 10 to 17 years of age
Published supporting passage
Anafranil ™ (clomipramine hydrochloride) Capsules USP is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).
All published source details
- Population
patients with Obsessive-Compulsive Disorder whose obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning (DSM-III-R); labeled effectiveness data include adults and children and adolescents 10 to 17 years of age
- Formulation or format
capsule
- Indication
treatment of obsessions and compulsions in Obsessive-Compulsive Disorder (OCD)
- Labeler
SpecGx LLC
- Product
ANAFRANIL (clomipramine hydrochloride) capsule
- Section code
34067-9
- Source collection coverage
- country:US
- Source pointer
- /sections/0
See something wrong? Tell us. Your note is private. We check sources before we change this page.